"Johnson & Johnson is deeply committed to progressing our rich pipeline of clinical-stage and pre-clinical drug candidates for atopic dermatitis," the company stated in a release.
As a chronic and often debilitating disease, where unmet need remains high, atopic dermatitis places both physical and emotional burdens on patients and their families.
The company is developing other experimental treatments for atopic dermatitis, including bispecific antibodies NM26, PX128 and PX130, as well as an oral STAT6 inhibitor, KP‑723, Reuters reported.
Eczema has multiple approved treatments, such as Sanofi and Regeneron's. Dupixent, AbbVie's Rinvoq, Pfizer's Cibinqo, Eli Lilly's Ebglyss, as well as some generic drugs such as cetirizine.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.